Aminoglutethimide Induced Hormone Suppression and Response to Therapy in Advanced Postmenopausal Breast Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 1983 Oct 1

PMID 6684948

Citations 10

Authors

A L Harris

M Dowsett

I E Smith

S Jeffcoate

Affiliations

Soon will be listed here.

Abstract

Eighty-one postmenopausal women with advanced breast cancer were studied for the effects of treatment with aminoglutethimide (AG) plus hydrocortisone on peripheral hormones and response to therapy. There were 40 responders (R) and 41 non-responders (NR) at 3 months from the start of treatment. Plasma oestrone concentrations were higher in non-responders at 1 and 2 months after starting AG (Means: NR 106 +/- 50, R 84 +/- 26 pmol l-1, P less than 0.05; highest value NR 121 +/- 51, R 99 +/- 24 pmol l-1, P less than 0.05). High oestrone levels were correlated with bulky liver secondaries, but not with age, tumour-free interval, time from last menstrual period, time from relapse to start of AG or body weight. Non-responders had higher mean prolactin levels on treatment (prolactin less than 500 mIUl-1 in 14/40 NR, 2/35 R, P less than 0.01). High oestrone or prolactin levels were present in 28/41 NR and 6/40 R (P less than 0.001). Dehydroepiandrosterone sulphate suppression did not differ between R and NR. The differences in peripheral endocrine environment in non-responding patients suggest that oestrogen metabolism may differ in non-responding patients and that sub-groups could be selected for rational endocrine therapy.

Citing Articles

Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.

Gradishar W, Yardley D, Layman R, Sparano J, Chuang E, Northfelt D Clin Cancer Res. 2015; 22(2):301-9.

PMID: 26324738 PMC: 5548297. DOI: 10.1158/1078-0432.CCR-15-0588.

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.

Dowsett M, Harris A, Smith I, Jeffcoate S Br J Cancer. 1984; 50(3):357-61.

PMID: 6540595 PMC: 1976801. DOI: 10.1038/bjc.1984.183.

Could aminoglutethimide replace adrenalectomy?.

Harris A Breast Cancer Res Treat. 1985; 6(3):201-11.

PMID: 3912013 DOI: 10.1007/BF01806770.

Modulation of natural killer cell activity in stage I postmenopausal breast cancer patients on low-dose aminoglutethimide.

Berry J, Green B, Matheson D Cancer Immunol Immunother. 1987; 24(1):72-5.

PMID: 3815420 PMC: 11038814. DOI: 10.1007/BF00199836.

Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer.

Miller A, Miller B, Hoffken K, SCHMIDT C Cancer Chemother Pharmacol. 1987; 20(4):337-41.

PMID: 3690808 DOI: 10.1007/BF00262588.

References

Iqbal M, Johnson M . Study of steroid-protein binding by a novel "two-tier" column employing Cibacron Blue F3G-A-Sepharose 4B. I-Sex hormone binding globulin. J Steroid Biochem. 1977; 8(9):977-83. DOI: 10.1016/0022-4731(77)90196-0. View

Tormey D, Simon R, Lippman M, Bull J, Myers C . Evaluation of tamoxifen dose in advanced breast cancer: a progress report. Cancer Treat Rep. 1976; 60(10):1451-9. View

Hawkins R, Roberts M, Forrest A . Oestrogen receptors and breast cancer: current status. Br J Surg. 1980; 67(3):153-69. DOI: 10.1002/bjs.1800670302. View

Hemsell D, GRODIN J, Brenner P, Siiteri P, MACDONALD P . Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab. 1974; 38(3):476-9. DOI: 10.1210/jcem-38-3-476. View

Santen R, Santner S, Davis B, Veldhuis J, SAMOJLIK E, Ruby E . Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab. 1978; 47(6):1257-65. DOI: 10.1210/jcem-47-6-1257. View

Lawrence B, Lipton A, Harvey H, Santen R, Wells Jr S, Cox C . Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. Cancer. 1980; 45(4):786-91. DOI: 10.1002/1097-0142(19800215)45:4<786::aid-cncr2820450429>3.0.co;2-x. View

Smith I, Fitzharris B, McKinna J, Fahmy D, Nash A, Neville A . Aminoglutethimide in treatment of metastatic breast carcinoma. Lancet. 1978; 2(8091):646-9. DOI: 10.1016/s0140-6736(78)92759-9. View

Harris A, Dowsett M, Jeffcoate S, Smith I . Aminoglutethimide dose and hormone suppression in advanced breast cancer. Eur J Cancer Clin Oncol. 1983; 19(4):493-8. DOI: 10.1016/0277-5379(83)90112-8. View

Swyer G, Lee A, MASTERTON J . Oestrogen excretion of patients with breast cancer. Br Med J. 1961; 1(5226):617-9. PMC: 1953521. DOI: 10.1136/bmj.1.5226.617. View

10.

Bates T, Rubens R, Bulbrook R, Goodwin P, Wang D, Knight R . Comparison of pituitary function and clinical response after transphenoidal and transfrontal hypophysectomy for advanced breast cancer. Eur J Cancer (1965). 1976; 12(10):775-82. DOI: 10.1016/0014-2964(76)90091-8. View

11.

Golder M, Phillips M, Fahmy D, Preece P, Jones V, Henk J . Plasma hormones in patients with advanced breast cancer treated with tamoxifen. Eur J Cancer (1965). 1976; 12(9):719-23. DOI: 10.1016/0014-2964(76)90022-0. View

12.

Bulbrook R, GREENWOOD F, Hadfield G, Scowen E . Oophorectomy in breast cancer; an attempt to correlate clinical results with oestrogen production. Br Med J. 1958; 2(5087):7-11. PMC: 2025880. DOI: 10.1136/bmj.2.5087.7. View

13.

McGuire W . Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol. 1978; 5(4):428-33. View

14.

Kley H, KRUSKEMPER H, Keck E . Estrone and estradiol in patients with cirrhosis of the liver: effects of ACTH and dexamethasone. J Clin Endocrinol Metab. 1976; 43(3):557-60. DOI: 10.1210/jcem-43-3-557. View

15.

GRODIN J, Siiteri P, MACDONALD P . Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab. 1973; 36(2):207-14. DOI: 10.1210/jcem-36-2-207. View

16.

JURET P, Hayem M . [Implantation of intrapituitary radioactive material (Au-198 and Y-90) in metastatic cancers of the breast. Clinical and biological review apropos of 75 cases]. Rev Fr Etud Clin Biol. 1961; 6:19-34. View

17.

Smith I, Harris A, Morgan M, Ford H, Gazet J, Harmer C . Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J (Clin Res Ed). 1981; 283(6304):1432-4. PMC: 1507612. DOI: 10.1136/bmj.283.6304.1432. View

18.

Victor A, Lundberg P, Johansson E . Induction of sex hormone binding globulin by phenytoin. Br Med J. 1977; 2(6092):934-5. PMC: 1631600. DOI: 10.1136/bmj.2.6092.934-a. View

19.

Santen R, SAMOJLIK E, Lipton A, Harvey H, Ruby E, Wells S . Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. Cancer. 1977; 39(6 Suppl):2948-58. DOI: 10.1002/1097-0142(197706)39:6<2948::aid-cncr2820390681>3.0.co;2-9. View

20.

Santen R, Worgul T, Lipton A, Harvey H, BOUCHER A, SAMOJLIK E . Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Intern Med. 1982; 96(1):94-101. DOI: 10.7326/0003-4819-96-1-94. View